Recent News

• 06.10.2025 - Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
• 06.10.2025 - Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
• 06.02.2025 - Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
• 06.02.2025 - Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
• 05.23.2025 - Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
• 05.23.2025 - Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
• 05.22.2025 - Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
• 05.22.2025 - Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants
• 05.15.2025 - Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update
• 05.15.2025 - Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Recent Filings

• 06.02.2025 - 8-K Current report
• 05.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.23.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.23.2025 - 8-K Current report
• 05.22.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - EX-99.1 EX-99.1